Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
No evidence of efficacy of 2 mg or 8 mg RSG XR monotherapy in cognition or global function was detected in the APOE-ε4-negative or other analysis populations.
-
In this 12-week trial, donepezil was not more effective than placebo in treating agitation in patients with Alzheimer's disease.
-
The target dose of 10 cm2 rivastigmine patch provides efficacy similar to the highest doses of capsules with a superior tolerability profile.
-
A long-term CMI in ChEI-treated early Alzheimer disease patients produced additional mood and cognitive benefits.
-
Treatment with ChEIs results in a modest but significant therapeutic effect and modestly but significantly higher rates of adverse events and discontinuation of treatment.
-
This study evaluated the efficacy and safety of donepezil in patients with mild to moderately severe Alzheimer's disease, and examined the relationships between plasma donepezil concentration, red blood cell acetylcholinesterase (AChE) activity and clinical response.
-
Gantenerumab significantly reduced PiB-PET uptake overall and in most regions and showed no changes in FDG-PET or MRI measures.
-
Pooled MMRM analyses showed a statistically significant effect of solanezumab across cognitive and functional outcome measures.
-
Seventeen studies were identified: thirteen cohort studies, two case-control studies, and two nested case-control studies.
-
The study included 524,975 older adults with dementia who were incident users of ChEIs (donepezil 80.72%, rivastigmine 16.41%, galantamine 2.87%).
-
73/100
The study included 47,059 older adults with dementia who were incident users of AChEIs.
-
The study cohort consisted of 178,441 older adults with dementia who were new users of ChEIs.
-
Several animal studies have showed the beneficial effects of physical exercise (PE) on brain function and health.
-
Twenty-one depressed patients with probable Alzheimer's disease (AD) were randomized to receive a 6-week treatment with clomipramine or placebo in a study with a double-blind crossover design.
-
We carried out a double-blind study of a vasopressin-related peptide, DGAVP citrate (Org 5667), in 115 patients with mild dementia, probable Alzheimer's type (DAT).
-
Monoclonal antibody (mAb) therapies targeting amyloid-beta (Aβ) plaques have gained prominence over the past decade as potential disease-modifying treatments for Alzheimer's disease (AD), leading to major regulatory approvals and global debate.
-
Lecanemab/Donanemab can improve memory, cognitive function, and daily living abilities in patients with early AD, significantly reduce the composite score of Alzheimer's disease, and inhibit the accumulation of amyloid peptides, thereby alleviating symptoms and improving the condition.
-
Despite most monoclonal antibodies against Aβ in Alzheimer's failed to demonstrate efficacy, the newest antibodies showed statistically significant clinical effects.
-
Alzheimer's disease, prevalent in individuals aged 60 and above, constitutes most dementia cases and significantly impairs memory and cognitive functions.
-
We aimed to summarise current evidence on different antidiabetic drugs to delay cognitive impairment, including mild cognitive impairment, dementia, Alzheimer's disease (AD) and vascular dementia, among subjects with type 2 diabetes mellitus (T2DM).
-
Infusion of bapineuzumab 0.5 or 1.0 mg/kg every 13 weeks for up to 3 years was generally well tolerated, with a safety and tolerability profile similar to that in previous studies.
-
Our findings demonstrate that 10-year CP exposure was associated with a 1.707-fold increase in the risk of developing AD.
-
Some observational studies raised concern that statins may cause memory impairment, leading to a US Food and Drug Administration warning.
-
The results indicate that lithium treatment may have beneficial effects on cognitive performance in subjects with MCI and AD dementia.
-
72/100
Compared to the control group of patients, patients previously exposed to exenatide had an advantage of 5.6 points (95% CI, 2.2-9.0; p = 0.002) using blinded video rating of the MDS-UPDRS part 3 motor subscale.
From across this topic
10 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Current and Emerging Therapeutic Approaches for Vascular Cognitive Impairment and Dementia
- A metaanalysis of controlled trials of neuroleptic treatment in dementia
- Alzheimer disease, attention, and the cholinergic system
- Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease
- Reducing placebo response in clinical trials of agitation in Alzheimer’s disease
- Risk of pneumonia in new users of cholinesterase inhibitors for dementia
- Lithium Therapy's Potential to Lower Dementia Risk and the Prevalence of Alzheimer's Disease: A Meta-Analysis
- Analysis of eligibility criteria in Alzheimer's and related dementias clinical trials
- Research and Development of Donepezil Hydrochloride, a New Type of Acetylcholinesterase Inhibitor
- Postmenopausal Estrogen and Prevention Bias